A simple combined intravenous/intramuscular regimen is described for lignocaine administration in the early vulnerable stage of myocardial infarction. Plasma levels in the therapeutic range are attained. This allows adequate drug protection during transport to hospital when an intravenous regimen may be impractical or impossible.
lie between 6*4 and 21 ,umol/l (1.5 to 5 jig/ml) two observers for changes in heart rate or rhythm.
( Harrison and Alderman, 1971; Collinsworth et al., The patients were given 100 mg lignocaine hydro-1974; Koch-Weser, 1975; Aps et al., 1976) . There chloride by intravenous injection over 2 minutes is difficulty in maintaining adequate plasma con-into an arm vein. Five minutes after the beginning centrations in the first two hours of treatment using of the intravenous injection, 300 mg were given by conventional intravenous dosage (Aps et al., 1976) . intramuscular injection into the deltoid muscle. The If such treatment is started in the patient's home, he time of the intramuscular injection was taken as is likely to be denied protection from arrhythmias zero time and 10 ml blood samples were taken from at a time when the risk is greatest and surveillance a vein in the other arm 2 minutes before zero time most difficult. and then at 3, 5, 10, 15, 30, 45, 60, 90, 120, 150, 180 , We report our experience using a simple com-and 240 minutes. The blood was centrifuged and bination of an intravenous bolus and intramuscular stored at 4°C until plasma concentrations were injection as a means of overcoming these difficulties. estimated. Plasma lignocaine was estimated by a gas chromaMethods tographic method. One ml samples of plasma, containing diphenhydramine 5 ,ug as an internal Twelve consecutive patients admitted to the standard, were made alkaline with 0 5 ml of 2M Coronary Care Unit, who fulfilled our criteria for NaOH. Samples were extracted with 5 ml portions lignocaine therapy (Walsh et al., 1972) (1.5 l±g/ml) in the first 2 hours. At 4 hours, only Results are mean of 10 patients ASEM.
4 patients had plasma levels above 6-4 lnol/l (1.5 jig/ml).
bolus of 1 to 2 mg/kg, followed by constant inThe mean drug half-life was 136-2 +29-3 fusion of 1 to 4 mg/min. Aps et al. (1976) have emminutes with a mean lignocaine clearance of phasised that this is associated with a period of 507 ml/min and volume of distribution of 82 litres. about 2 hours when the plasma concentration is The range of values are shown in the Table. subtherapeutic and have recommended a more complex regimen involving different and reducing rates Discussion of infusion. We have found that meticulous control of intravenous infusion flow rates is very difficult In myocardial infarction the commonest cause of during travel in an ambulance and an alternative death is ventricular arrhythmia occurring in the seemed desirable. The combination of an intraearly phase of the attack (Pantridge and Geddes, venous bolus and intramuscular injection was a 1967). The generally accepted first line drug to possible answer, and we were pleased to find that in counter this is lignocaine and there is some clinical all our patients therapeutic levels were maintained evidence that its early use may lower mortality long enough to allow transport from home to hos- (Morgensen, 1970; Valentine et al., 1974) .
pital. The mean plasma concentrations in the first The usual lignocaine regimen is an intravenous two hours of treatment were similar to those re- Table Plasma 0 0075  733  98  10 2-1 9-8 13-7 12-8 13-2 11-5 13-2 11-5 9.4 9 0 9-8 8-5 7-7 376-3 0-0018 257 142 Mean 18-5 18-6 18-7 21-9 19-2 16-5 16-8 13-7 11-0 9-3 7-1 5-9 136-2 0-0064 507 82 SEM 5-2 3-6 1-8 1-7 2-4 2-1 1-6 1-8 1-4 1-2 1-4 10 0 9 29-3 0-0008 51 9
Conversion: SI to traditional units-lignocaine: 1 Ztmol/l 0-23 ILg/ml. (Boyes et al., 1971 ) and in patients after London. myocardial infarction (Prescott and Nimmo, 1971 ). Valentine, P. A., Frew, J. L., Mashford, M. L., and Sloman,
